Generic Name: brentuximab vedotin

Pronunciation: N/A

Abbreviation: N/A

Other Market Name: N/A

Drug Class: Targeted Therapy Medications

Company: Seattle Genetics

Approval Status: Approved

Generic Version Available: No

Experimental Code: N/A

Drug Indication

Adcetris is a CD30-directed antibody-drug conjugate approved for anaplastic large cell lymphoma and classical Hodgkin lymphoma.


General Info

Adcetris consists of an antibody that binds to the CD30 receptor on cancerous B cells plus the strong chemotherapy drug monomethyl auristatin E. This drug is too toxic to use as a systemic medication by itself, but the antibody carries it directly to cancer cells.

Clinical trials showed that Adcetris slows disease progression in people with anaplastic large cell lymphoma and classical Hodgkin lymphoma.


Dosing Info:

Adcetris is an intravenous infusion administered every two or three weeks.

Side Effects

Common side effects include fatigue, nausea, constipation, diarrhea, fever and peripheral neuropathy. Adcetris can cause depletion of white blood cells (neutropenia), which can lead to infections, including fatal opportunistic infections. Other potentially serious side effects include liver toxicity, lung toxicity, severe skin reactions and tumor lysis syndrome, or metabolic abnormalities that can occur when many cancer cells are killed at once.

For More Info:

Co-Pay Program Info:

Patient Assistance Program Info:

Last Reviewed: November 16, 2018